FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Edscharp who wrote (32)	10/9/1999 1:34:00 AM
From: Edscharp	Read Replies (1) of 75

Since it's timely, I can't resist mentioning one other stock that is in the "ImClone" category. Isis Pharmaceutical (ISIP) is rapidly approaching the long awaited results of their P3 trials on their compound ISIS 2302 for Crohn's disease. Again, great results on P2 trials and a large target group for this indication. However, what makes Isis particularly compelling is that they are the lead company in the field of "anti-sense" technology. Their large patent position in antisense will allow them to completely dominate this field of research. If ISIS 2302 is approved, it will be the second anti-sense drug to be marketed by Isis and will establish beyond any reasonable doubt the "proof of concept" of this technology. The potential applications for anti-sense are vast. With approval of ISIS 2302 this could be one of the best long-term holds ever.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next